Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 1215 results for pain

  1. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

  2. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  4. Radiofrequency tissue reduction for turbinate hypertrophy (HTG343)

    Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.

  5. Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)

    Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.

  6. Phototherapeutic laser keratectomy for corneal surface irregularities (HTG231)

    Evidence-based recommendations on phototherapeutic laser keratectomy for corneal surface irregularities. This involves using a laser to remove layers of the cornea in order to produce a smooth, even surface with the aim of improving vision.

  7. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  8. Interstitial laser therapy for breast cancer (HTG55)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

  9. Uterine artery embolisation for fibroids (HTG240)

    Evidence-based recommendations on uterine artery embolisation for fibroids. This involves injecting small particles into the blood vessels that take blood to the uterus, via the groin.

  10. Needle fasciotomy for Dupuytren's contracture (HTG21)

    Evidence-based recommendations on needle fasciotomy for Dupuytren's contracture. This involves cutting one or more fibrous bands using a blade or a bevel of a needle.

  11. Stapled transanal rectal resection for obstructed defaecation syndrome (HTG224)

    Evidence-based recommendations on stapled transanal rectal resection for obstructed defaecation syndrome. This involves removing the damaged part of the rectum and joining the remaining parts back together.

  12. Therapeutic sialendoscopy (HTG140)

    Evidence-based recommendations on therapeutic sialendoscopy. This involves using a flexible tube to enter the salivary gland, and visualise and remove the stone.

  13. Laparoscopic laser myomectomy (HTG9)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

  14. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.